Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) is a clinical-stage company developing first-in-class medicines for disorders of the central nervous system, including fibromyalgia, post-traumatic stress disorder (PTSD) and episodic tension-type headaches. The company’s leading candidate, TNX-102 SL, is intended to be a first-line treatment for fibromyalgia and PTSD. The company will initiate a Phase III program for TNX-102 SL in the second quarter of 2015 to support product registration in the U.S. For more information, visit the company’s website at www.tonixpharma.com.

Noble Financial Capital Markets, an equity research driven, full-service, investment banking boutique, is hosting its tenth annual equity conference in Sandpiper Bay, FL. Attended by institutional investors from across North America, the event features more than 140 public company executive teams from a diverse range of industries. For more information, visit www.noble.missionir.com.